The PPD Shot: Is It a Vaccine for Tuberculosis or a Test?

The PPD shot is a test for tuberculosis exposure, not a vaccine. It contains no live or dead bacteria and cannot protect you against TB. The confusion is understandable because the PPD skin test involves an injection, and many people who receive it are also told about BCG, the actual TB vaccine used widely outside the United States. But the two serve completely different purposes, and mixing them up can lead to real misunderstandings about your health status and what your results mean.

What PPD Actually Is

PPD stands for purified protein derivative. It is a standardized extract made from proteins of the bacterium that causes tuberculosis, Mycobacterium tuberculosis. When a small amount is injected just under the skin of your forearm, it does not infect you, immunize you, or change your immune status in any way. It simply asks your immune system a question: have you encountered TB bacteria before? If your body’s immune cells recognize those proteins, the injection site swells into a firm bump over the next two to three days. If your immune system has never seen TB, the site stays flat.

The test goes by several names. Clinicians call it the tuberculin skin test (TST) or the Mantoux test. Patients often call it “the TB test,” “the PPD test,” or “the PPD shot.” Whatever you call it, the principle is the same: a tiny dose of TB protein is placed under the skin, and you come back 48 to 72 hours later so a healthcare worker can measure the response.

How the Test Is Given and Read

A healthcare worker injects a small amount of PPD solution into the top layer of skin on the inner surface of your forearm using a very fine needle. When done correctly, a small, pale raised area about 6 to 10 millimeters across appears at the injection site immediately.¹ This little wheal is just the fluid sitting under the skin and disappears within minutes. It is not the result.

The real reading happens when you return two to three days later. The healthcare worker feels your forearm for induration, which is the firm, raised bump that develops if your immune system has responded. This is the critical distinction: they measure the hard bump, not any redness or bruising around it.¹ A large red area with no firmness underneath is not a positive test. Many people assume that any visible mark means they are positive, but redness alone does not count. Only the diameter of the firm bump matters, and that measurement is interpreted differently depending on your risk profile.

What Counts as a Positive Result

There is no single number that means “positive” for everyone. The cutoff depends on who you are and how likely you are to have been exposed to TB. For people with HIV or those who are severely immunocompromised, an induration of 5 millimeters or more is considered positive. For most other adults with some risk factors, the threshold is 10 millimeters. For people with no known risk factors in low-prevalence areas, 15 millimeters is sometimes used. These thresholds exist because the test is not perfectly precise, and lowering the bar for high-risk groups helps catch infections that would be dangerous to miss.

One complication is that different strengths of PPD solution exist worldwide. A study comparing two common strengths found that the results did not agree well with each other, with one strength flagging significantly more people as positive than the other.² This means that a test result from one country using one formulation may not be directly comparable to a result obtained elsewhere using a different one. If you have been tested in multiple countries and gotten different results, the formulation used may be part of the explanation.

Why Your Immune System Reacts

The bump that forms at the injection site is a delayed-type hypersensitivity reaction, a specific kind of immune response driven by T cells rather than antibodies. When someone has been infected with TB bacteria (or vaccinated with BCG), their immune system develops T cells that remember TB proteins. When PPD is injected, those memory T cells rush to the site, recognize the proteins, and trigger a localized inflammatory response.³ This inflammation is what creates the firm swelling.

The “delayed” part is why you cannot read the test immediately. Unlike an allergic reaction to a bee sting, which peaks within minutes, this cell-mediated response takes 48 to 72 hours to fully develop. Reading the test too early or too late gives unreliable results.

BCG Is the Actual TB Vaccine

The real tuberculosis vaccine is called BCG, which stands for Bacillus Calmette-Guérin. It is a live but weakened form of a bacterium closely related to the one that causes TB. Unlike PPD, BCG is designed to train the immune system to fight TB before an actual infection occurs.⁴ Because the bacteria in BCG are alive (though weakened), they persist in the body for some time after vaccination, and this persistence appears to be part of how the vaccine maintains its protective effect.⁵

BCG is one of the most widely administered vaccines in the world, given at birth or during infancy in most countries outside the United States, Canada, and parts of Western Europe. The United States does not routinely use BCG because TB rates are relatively low and, more importantly, because BCG vaccination complicates the interpretation of the PPD test. That complication is at the heart of much of the confusion between the two.

How BCG Vaccination Muddles PPD Results

This is the practical problem millions of people face. If you received BCG as a child (as most people born outside the U.S. did), your immune system learned to recognize TB proteins from the vaccine. When you later receive a PPD test, your T cells may react to the injected proteins not because you have a TB infection but because they remember the vaccine. A meta-analysis found that BCG-vaccinated individuals were roughly twice as likely to test positive on a PPD test compared to unvaccinated individuals, even when they did not have active TB.⁶

This creates a frustrating cycle for many immigrants to the United States. You arrive, your employer or school requires a TB test, you receive the PPD, and it comes back positive because of a vaccination you received as a baby. You do not have TB, but the test cannot tell the difference between vaccine-induced immunity and actual infection. The standard next step is a chest X-ray to rule out active TB, and some people end up being offered preventive treatment for latent TB they may never have had. This is one of the most common healthcare headaches for people born in countries where BCG is routine.

Blood Tests That Avoid the BCG Problem

Interferon-gamma release assays (IGRAs) are blood tests developed specifically to get around the false-positive problem caused by BCG. Instead of injecting PPD under the skin, a blood sample is drawn and mixed with proteins that are found in M. tuberculosis but not in the BCG vaccine strain. The key proteins used, called ESAT-6 and CFP-10, are present in TB bacteria but absent from BCG, so the test can distinguish between someone who was vaccinated and someone who was actually infected.⁷

Research on children and adolescents who had received BCG vaccination confirmed that IGRAs are more specific than the skin test in this group, meaning they produce fewer false positives.⁸ However, the skin test may be more sensitive, meaning it catches a wider net of infected people and misses fewer true cases. Neither test is perfect. The trade-off is between catching every possible case (skin test) and avoiding unnecessary follow-ups in vaccinated populations (blood test). For BCG-vaccinated individuals in low-prevalence countries, many guidelines now recommend the blood test as the first-line option.

One limitation worth knowing: IGRAs require a functioning lab, refrigerated transport of blood samples, and processing within a set time window. They also cost more than a PPD test. In resource-limited settings where TB is most common, the skin test remains the more practical choice despite its limitations.

The Booster Phenomenon and Two-Step Testing

If you have not been exposed to TB in a long time, or if your BCG-induced immunity has faded, your first PPD test might come back negative even though your immune system does technically recognize TB proteins. The act of receiving that first test can “wake up” dormant immune memory, a phenomenon called boosting. If you are tested again a week or two later, the second result may be positive, not because you caught TB between tests but because the first injection reminded your immune system of a response it had almost forgotten.

This is why some employers, particularly hospitals and long-term care facilities, use two-step testing for new employees. The first test establishes a baseline, and the second test, administered one to three weeks later, checks whether the first test triggered a booster response. The goal is to distinguish between a genuine new TB infection and a revived old immune memory.⁹ Without two-step testing, an employee’s future annual test might come up positive and be falsely interpreted as a new infection acquired at work.¹⁰

A study in a veterans domiciliary found that the initial positive rate of about 39% jumped to nearly 47% after two-step testing, meaning a substantial number of people had genuine but dormant immune memory that only showed up on the second round.¹¹ If those individuals had been tested only once, their future positive results would have been misclassified as new conversions.

Children and Screening Approaches

Tuberculin skin testing in children has shifted over the past few decades. In 1996, the American Academy of Pediatrics recommended moving away from universal screening and toward targeted testing, meaning that only children with specific risk factors for TB exposure should be tested.¹² Risk factors include living in a household with someone who has TB, being born in or traveling to a country where TB is common, and having close contact with high-risk adults.

The reasoning is straightforward: in a country with low TB prevalence, testing millions of children who have virtually no chance of exposure produces many more false positives than true positives. Each false positive means unnecessary follow-up, chest X-rays, parental anxiety, and sometimes unneeded medication. Targeted screening focuses resources where they are most likely to find actual infections. For children who have received BCG, the blood test is often preferred for the same reasons it is preferred in BCG-vaccinated adults.

Supply Shortages and Their Consequences

PPD solution has experienced recurring supply disruptions that have directly affected TB screening. In the United States, a shortage in 2013 affected at least 29 of 52 jurisdictions to the point that health department screening activities were interrupted.¹³ Europe experienced a similar shortage in 2014 that forced multiple countries to alter their screening practices.¹⁴

These shortages are not minor logistical hiccups. TB screening programs depend on a steady supply of PPD, and when it runs out, contact investigations stall, new healthcare workers cannot be cleared to start their jobs, and immigrant health screenings are delayed. The shortages have pushed some institutions to adopt IGRAs faster than they otherwise would have, which may have a silver lining given the blood test’s advantages for BCG-vaccinated populations. But in settings where the blood test infrastructure does not exist, a PPD shortage means screening simply stops.

PPD in Veterinary Medicine

The PPD skin test is not just a human diagnostic tool. It is also the primary method for detecting bovine tuberculosis in cattle, using a version of the test called the single intradermal comparative cervical tuberculin (SICCT) test. Cattle are injected with two types of tuberculin, one from the bovine TB strain and one from an avian strain, and the difference in skin reactions helps identify infected animals.¹⁵

The same challenges that plague human PPD testing show up in cattle. Animals exposed to environmental mycobacteria (harmless relatives of the TB bacterium found in soil and water) can develop false-positive results, just as BCG-vaccinated humans do. The protein ESAT-6, which is used in human blood tests to distinguish vaccine responses from true infection, has also been shown to differentiate TB-infected cattle from those reacting to environmental bacteria or BCG vaccination.⁷ Bovine TB control programs in the British Isles and elsewhere depend heavily on skin testing, and a false positive in a herd can trigger slaughter policies, making test accuracy an economic issue as well as a health one.

When People with Weakened Immune Systems Are Tested

The PPD test relies on a functioning immune system to produce a response. If someone’s immune system is suppressed, whether by HIV, organ transplant medications, chemotherapy, or autoimmune disease treatments, they may not mount a visible reaction even if they are genuinely infected with TB. This is called a false negative, and it is one of the most dangerous failure modes of the test because the people most vulnerable to severe TB disease are the same ones most likely to have a muted skin test response.

This problem also affects blood tests, though to a somewhat different degree. Research has examined how immunosuppressant medications used in autoimmune rheumatic diseases affect the immune cells’ ability to respond to the specific TB proteins (ESAT-6 and CFP-10) used in IGRAs.¹⁶ The concern is that immunosuppression dampens the very immune response both tests depend on, potentially causing missed diagnoses. For immunocompromised patients, clinicians often use lower cutoff thresholds for skin tests (5 mm instead of 10 mm) and may combine multiple testing methods or rely more heavily on clinical judgment and imaging.

Why the Confusion Persists

Several factors keep the PPD-versus-vaccine mix-up alive. The PPD test is given as an injection, which in most people’s minds equals a shot, which equals a vaccine. Many people receive the PPD test at the same clinic visit where they get actual vaccines, blurring the distinction further. In countries where BCG is given at birth, parents may vaguely recall being told their child “got the TB shot” and later assume the PPD test in adulthood is the same thing or a booster. Healthcare workers sometimes use shorthand that does not help: “we need to give you your TB shot” can refer to either one depending on context.

The practical consequences of this confusion are real. Someone who believes the PPD is a vaccine may think they are protected against TB when they are not. Someone who tests positive and is told it might be from “the vaccine they got as a baby” may not understand whether they need treatment or further testing. And someone who refuses a PPD test because they “already got the TB vaccine” may miss a genuine infection. The clearest way to keep them straight: PPD asks a question, BCG provides protection. One reads your immune history; the other writes it.